Jan 22, 2024 ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
Nov 20, 2023 ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
Nov 14, 2023 ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
Sep 6, 2023 ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference